While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizer’s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.
